FXYD Domain Containing Ion Transport Regulator 5 (FXYD5) ELISA Kits

Human FXYD Domain Containing Ion Transport Regulator 5 (FXYD5) interaction partners

1. the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion.

2. Knockdown of FXYD5 in MDA-MB-231 breast cancer cells largely decreases expression and secretion of the chemokine CCL2 (MCP-1). A related effect has also been observed in renal cell carcinoma cells.

3. Study demonstrated that the expression of FXYD1, FXYD3 and FXYD5 is elevated in the lungs of Acute respiratory distress syndrome patients

4. Dysadherin-silenced side population cells exhibited reduced expression of Bcl-2 and Bax compared with that prior to silencing.

5. we are focusing on the role of dysadherin in E-cadherin downregulation, the various expression patterns of the molecule in head and neck cancer

6. Findings suggest that dysadherin might contribute to breast cancer progression through AKT activation.

7. These results suggest a role of let-7a down-regulation in the development of thyroid neoplasias of the follicular histotype, likely regulating dysadherin protein expression levels.

8. Data show that osteoblasts are the major cell type of the bone marrow that affect RCC cells by secreting factors that increase the expression of dysadherin and CCL2 in the tumor cells leading to enhanced cell migration.

9. This is the first report on expression of dysadherin in the male gonad and in spermatozoa.

10. Overexpression of Snail, Slug, and dysadherin and activation of Wnt and PI3K/Akt signaling was associated with inactivated E-cadherin in the spindle cells of monophasic fibrous synovial sarcomas.

11. Combined dysadherin-positive expression and E-cadherin-negative expression may be valuable information for predicting aggressive tumor behavior of differentiated-type gastric carcinoma with submucosal invasion

12. transfection of dysadherin cDNA into the liver cancer cell line PLC/PRF/5 enhanced the properties of cencer stem cells, including anti-apoptosis, their sphere-forming ability, side population phenotype, and tumor initiation ability in vivo

13. In lung carcinomas dysadherin expression seems to reflect tumour aggressiveness and may be considered a positive marker of poor prognosis when considered alone or/and in combination with down-regulation of E-cadherin.

14. The detection of dysadherin in tumors and cytokeratin in the lymph nodes may be a potential significant indicator of a poor prognosis for patients who undergo complete resection of stage I non-small cell lung cancer

15. We report the cloning and characterization of a cancer-associated cell membrane glycoprotein recognized by mAb NCC-3G10.

16. dysadherin expression was significantly associated with the prognosis, occurrence of secondary undifferentiated carcinomas, size of the primary tumor, and metastasis to the regional lymph nodes and lungs

17. dysadherin has a role in hematogenous metastasis of gastric cancer

18. Dysadherin and E-cadherin expression may help to predict the prognosis of patients with ESCC (esophageal squamous cell carcinoma).

19. Dysadherin is able to modulate actin structures, stimulate cell motility, and contribute directly to the metastatic potential of human pancreatic cancer cells.

20. dysadherin may be a valuable prognostic marker in cervical carcinoma.

Mouse (Murine) FXYD Domain Containing Ion Transport Regulator 5 (FXYD5) interaction partners

1. FXYD5 mediates metastatic progression through regulation of the beta Na(+)-K(+)-ATPase subunit in the 4T1 mouse breast cancer model.

2. transfection of M1 epithelial cell line with FXYD5 largely increases lipopolysaccharide (LPS) stimulated CCL2 mRNA and secretion of the translated protein

3. FXYD5 affects cell polarization through its interaction with Na(+)-K(+)-ATPase.

4. Expressing FXYD5 in mouse kidney collecting duct cell line M1 led to a large decrease in amiloride-insensitive transepithelial electrical resistance as well as increased permeability to 4-kDa dextran.

5. The role of FXYD5 in Na,K-ATPase activity, its cellular and tissue distribution, and its biochemical properties are reported.

6. data suggest that different FXYD proteins interact similarly with the Na(+)-K(+)-ATPase and their transmembrane domains

7. FXYD5 is significantly increased in the lungs and nasal epithelium of cystic fibrosis mice as assessed by RT-PCR.